Opakalim (BHV-7000) is a selective Kv7.2/7.3 potassium channels activator with an EC 50 of 0.6 μM. Opakalim shows minimal GABAA receptor activation and exhibits potent anti-seizure efficacy in the maximal electroshock seizure (MES) model. Opakalim can be used for the study of seizures [1] [2].
In Vivo, Opakalim provides protection against seizures with a brain EC50 of 0.12 μM and TD50 >20 mg/kg in the maximal electroshock seizure rats model[2].
References:
[1]. Bharat Awsare, et al. Phase 1 Study Evaluating the Safety and Tolerability of BHV-7000, a Novel, Selective Kv7.2/7.3 Potassium Channel Activator, in Healthy Adults (P8-1.007). April 9, 2024 issue.
[2]. Picchione K, et al. Characterization of BHV-7000: A Novel Kv7. 2/7.3 Activator for the Treatment of Seizures (S29. 006)[C]//Neurology. Hagerstown, MD: Lippincott Williams & Wilkins, 2024, 102(7_supplement_1): 6119.
In Vivo, Opakalim provides protection against seizures with a brain EC50 of 0.12 μM and TD50 >20 mg/kg in the maximal electroshock seizure rats model[2].
References:
[1]. Bharat Awsare, et al. Phase 1 Study Evaluating the Safety and Tolerability of BHV-7000, a Novel, Selective Kv7.2/7.3 Potassium Channel Activator, in Healthy Adults (P8-1.007). April 9, 2024 issue.
[2]. Picchione K, et al. Characterization of BHV-7000: A Novel Kv7. 2/7.3 Activator for the Treatment of Seizures (S29. 006)[C]//Neurology. Hagerstown, MD: Lippincott Williams & Wilkins, 2024, 102(7_supplement_1): 6119.